<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01877915</url>
  </required_header>
  <id_info>
    <org_study_id>CR101940</org_study_id>
    <secondary_id>RIVAROXHFA3001</secondary_id>
    <secondary_id>2013-000046-19</secondary_id>
    <nct_id>NCT01877915</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure</brief_title>
  <acronym>COMMANDER HF</acronym>
  <official_title>A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness and safety of rivaroxaban compared
      with placebo (inactive medication), in reducing the risk of death, myocardial infarction or
      stroke in participants with heart failure and significant coronary artery disease following
      an episode of decompensated heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (the study medication is assigned by chance), double-blind (neither
      physician nor participant knows the identity of the assigned treatment), parallel group (each
      participant group receives different treatments simultaneously), event driven (the study
      duration is determined by the time taken for a specific number of events to occur),
      multicenter study to assess the effectiveness and safety of rivaroxaban compared with
      placebo, in reducing the risk of death, myocardial infarction or stroke in participants with
      heart failure and significant coronary artery disease following an episode of decompensated
      heart failure. Participants will be randomly assigned in a 1:1 ratio to receive either
      rivaroxaban or placebo (each in addition to standard of care for heart failure and coronary
      artery disease as prescribed by their managing physician). The study will consist of a
      screening phase, a double-blind treatment phase, and a follow-up after the sponsor-announced
      global treatment end date (GTED, defined as the date when 1200 primary efficacy outcome
      events are predicted to have occurred). The double-blind treatment phase is estimated to last
      for 6 to 54 months. Participants will discontinue study drug after taking both their morning
      and evening doses on the GTED and will return to the study center for the end-of-study visit
      (between 15 and 45 days but no sooner than 15 days after the GTED). Patient safety will be
      monitored throughout the study. The average study duration for participants is expected to be
      approximately 29 months. The study drug, rivaroxaban, is approved in the United States and in
      multiple countries around the world for the prevention and treatment of a number of
      thrombosis-mediated conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 10, 2013</start_date>
  <completion_date type="Actual">April 19, 2018</completion_date>
  <primary_completion_date type="Actual">April 19, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke</measure>
    <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
    <description>Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability</measure>
    <time_frame>Up to 227 Weeks</time_frame>
    <description>Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)</measure>
    <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
    <description>Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Cardio Vascular Death</measure>
    <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
    <description>Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Re-Hospitalization for Worsening of Heart Failure</measure>
    <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
    <description>Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)</measure>
    <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
    <description>Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure</measure>
    <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
    <description>Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of Bleeding Events That Requiring Hospitalization</measure>
    <time_frame>Up to 227 Weeks</time_frame>
    <description>Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event</measure>
    <time_frame>Up to 227 Weeks</time_frame>
    <description>Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5081</enrollment>
  <condition>Heart Failure</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Rivaroxaban 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant will receive 2.5 mg of rivaroxaban twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each participant will receive matching placebo twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
    <arm_group_label>Rivaroxaban 2.5 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care for heart failure and coronary artery disease</intervention_name>
    <description>Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Rivaroxaban 2.5 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have symptomatic heart failure for at least 3 months prior to Screening

          -  Participants must have an episode of decompensated heart failure (index event)
             requiring (a) an overnight stay [that is, staying past midnight] in a hospital,
             emergency department, or medical facility with the capability of treating with
             intravenous medications and observing heart failure patients before randomization or
             (b) an unscheduled outpatient visit to a heart failure management center, where
             parenteral therapy is required for heart failure stabilization. An episode of
             decompensated heart failure is defined as symptoms of worsening dyspnea or fatigue,
             objective signs of congestion such as peripheral edema or ascites, and/or adjustment
             of pre-hospitalization/outpatient visit heart failure medications. Participants are
             eligible for randomization at discharge from the facility treating the index event and
             up to 30 days after discharge if they are in stable condition

          -  Must have a documented left ventricular ejection fraction (LVEF) of less than or equal
             to 40 percent (%) within 1 year before randomization

          -  Must have evidence of significant coronary artery disease

          -  Must be medically stable in terms of their heart failure clinical status at the time
             of randomization

          -  Must have a brain natriuretic peptide (BNP) level greater than or equal to (&gt;=) 200
             picogram per milliliter (pg/mL) or N-terminal-proBNP (NT-proBNP) level &gt;=800 pg/mL
             (preferred assay) during the Screening period and before randomization

        Exclusion Criteria:

          -  Any condition that, in the opinion of the investigator, contraindicates anticoagulant
             therapy or would have an unacceptable risk of bleeding, such as, but not limited to,
             active internal bleeding, clinically significant bleeding, bleeding at a
             noncompressible site, or bleeding diathesis within 28 days of randomization

          -  Severe concomitant disease such as (a) atrial fibrillation (AFib) or another condition
             that requires chronic anticoagulation (participants with isolated transient AFib may
             be allowed at the discretion of the treating physician investigator) and (b)
             Documented acute myocardial infarction (MI) during index event

          -  Prior stroke within 90 days of randomization

          -  Has been hospitalized for longer than 21 days during the index event

          -  Planned intermittent outpatient treatment with positive inotropic drugs administered
             intravenously
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Alexander City</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlantis</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallahassee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cumming</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucker</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairview Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockford</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merrillville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munster</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Bend</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabethtown</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Owensboro</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bossier City</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hammond</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slidell</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Randallstown</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mount Clemens</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pontiac</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bridgewater</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elmer</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haddon Heights</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manalapan</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sewell</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cortlandt Manor</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jamaica</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinehurst</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fairfield</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bartlesville</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Doylestown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sayre</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sellersville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cypress</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kingwood</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>McKinney</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellingham</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bahia Blanca</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma de Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Córdoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mendoza</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merlo</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Quilmes</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Resistencia</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Nicolas</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santiago del Estero</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vicente Lopez</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedford</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cairns</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Concord</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hobart</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Launceston</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sydney</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wollongong</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Woolloongabba</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belo Horizonte</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belém</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blumenal</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasília</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campina Grande do Sul</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campinas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Campo Grande</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Canoas</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Curitiba</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goiânia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marília</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Passo Fundo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Recife</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ribeirão Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salvador</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Jose do Rio Preto</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Pedro</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tatuí</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uberlândia</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Votuporanga</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blagoevgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burgas</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dimitrovgrad</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kazanlak</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pazardzhik</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plovdiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ruse</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stara Zagora</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veliko Tarnovo</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maple Ridge</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. John's</city>
        <state>Newfoundland and Labrador</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scarborough</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daqing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haikou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hunan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jining</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lanzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Qingdao</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shenyang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shijiazhuang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taiyuan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xi'an</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Xian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yang Zhou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yichang</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hodonín</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hradec Králové</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hranice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Karlovy Vary</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kladno</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kolín</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Litomyšl</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mladá Boleslav</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olomouc</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plze?-Bory</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 10</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 8 - Libe?</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Slany</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Teplice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uherské Hradišt?</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valašské Mezi?í?í</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hjørring</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Køge</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Besancon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chambray-Lès-Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corbeil Essonnes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pau</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vandoeuvre-les-nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Konstanz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Langen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ludwigshafen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magdeburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Markkleeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Papenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Witten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heraklion -Crete</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Larisa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Thessalonikis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voula</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balatonfüred</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berettyóújfalu</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyor</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miskolc</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagykanizsa</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szekszárd</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Székesfehérvár</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chikushino-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ehime</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hatsukaichi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hitachi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hyogo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ishikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izumo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kahoku-District</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kobe-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Komatsushima-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koshigaya-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miyazaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagano-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagano</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Niigata</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sendai</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shiga</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shimane</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shizuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tachikawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Takaraduka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokushima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyoake</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tsu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wakayama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yamaguchi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yatsushiro</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yonago</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cheongju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuldiga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sigulda</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ventspils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alytus</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaunas</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Klaipeda</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Panevezys</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Siauliai</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cheras</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johor Bahru</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kota Kinabalu</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kuching</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Selayang</city>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benito Juárez</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chihuahua</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Culiacan</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>León</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico City</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oaxaca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pachuca</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Puebla</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Queretaro</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Luis Potosí</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Veracruz</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almere</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Blaricum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deventer</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Doetinchem</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ede</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Heerlen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Helmond</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Meppel</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tilburg</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Będzin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inowrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kutno</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lubin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Myslenice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olsztyn</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostroleka</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ostrowiec Swietokrzyski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oswiecim</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plock</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pulawy</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rabka-Zdrój</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Skierniewice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Starogard Gdanski</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torun</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wloclawek</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zabrze</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zamosc</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Łódż</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almada</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aveiro</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braga</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carnaxide</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coimbra</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Covilhã</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leiria</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lisboa</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Matosinhos</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viana do Castelo</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vila Real</city>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baia Mare</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Braila</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buzau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cluj-Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Craiova</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Focsani</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Galati</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pitesti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targu-Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Timisoara</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chita</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivanovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Izhevsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kaluga</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Krasnoyarsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kursk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow, Zelenograd</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nizhny Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orenburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perm</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostov on Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ryazan</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bardejov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lucenec</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moldava nad Bodvou</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nitra</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Povazska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Svidnik</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Centurion</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pinelands</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tongaat</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>A Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Almería</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Avila</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burgos</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cáceres</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elche</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Coruña</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Majadahonda</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olot</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orihuela</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sanlúcar de Barrameda</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sant Joan Despí</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrevieja</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Viladecans</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ljungby</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Diyarbakir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eskisehir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kahramanmaras</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kocaeli</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Konya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kırıkkale</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mersin</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sivas</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnipro</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lutsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnitsa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vinnytsia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhia</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zhytomir</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aberdeen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Airdrie</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chesterfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chichester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clydebank</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dudley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Kilbride</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Inverness</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ta1 5da</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wirral</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 12, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2013</study_first_posted>
  <results_first_submitted>April 18, 2019</results_first_submitted>
  <results_first_submitted_qc>April 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 10, 2019</results_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Stroke</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 1, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT01877915/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/15/NCT01877915/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 3 participants randomized twice were only counted once in the ITT analysis set (comprised of 5,022 participants).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Rivaroxaban</title>
          <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2507"/>
                <participants group_id="P2" count="2515"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2453"/>
                <participants group_id="P2" count="2447"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="68"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rivaroxaban</title>
          <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2507"/>
            <count group_id="B2" value="2515"/>
            <count group_id="B3" value="5022"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.5" spread="10.07"/>
                    <measurement group_id="B2" value="66.3" spread="10.27"/>
                    <measurement group_id="B3" value="66.4" spread="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="551"/>
                    <measurement group_id="B2" value="599"/>
                    <measurement group_id="B3" value="1150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1956"/>
                    <measurement group_id="B2" value="1916"/>
                    <measurement group_id="B3" value="3872"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="309"/>
                    <measurement group_id="B2" value="300"/>
                    <measurement group_id="B3" value="609"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2186"/>
                    <measurement group_id="B2" value="2203"/>
                    <measurement group_id="B3" value="4389"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="365"/>
                    <measurement group_id="B3" value="727"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2063"/>
                    <measurement group_id="B2" value="2065"/>
                    <measurement group_id="B3" value="4128"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="362"/>
                    <measurement group_id="B2" value="365"/>
                    <measurement group_id="B3" value="727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="258"/>
                    <measurement group_id="B2" value="251"/>
                    <measurement group_id="B3" value="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1799"/>
                    <measurement group_id="B2" value="1807"/>
                    <measurement group_id="B3" value="3606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>ARGENTINA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUSTRALIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BRAZIL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="80"/>
                    <measurement group_id="B3" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BULGARIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="314"/>
                    <measurement group_id="B2" value="314"/>
                    <measurement group_id="B3" value="628"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CANADA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHINA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="186"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CZECH REPUBLIC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DENMARK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FRANCE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GERMANY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GREECE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HUNGARY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ITALY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>JAPAN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LATVIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LITHUANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MALAYSIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MEXICO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="73"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NETHERLANDS</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POLAND</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                    <measurement group_id="B2" value="290"/>
                    <measurement group_id="B3" value="578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PORTUGAL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ROMANIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="200"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUSSIAN FEDERATION</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="274"/>
                    <measurement group_id="B2" value="276"/>
                    <measurement group_id="B3" value="550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SLOVAKIA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOUTH AFRICA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SOUTH KOREA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SPAIN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SWEDEN</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TURKEY</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UKRAINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="264"/>
                    <measurement group_id="B2" value="265"/>
                    <measurement group_id="B3" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED KINGDOM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>UNITED STATES</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke</title>
        <description>Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events.</description>
        <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
        <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of All-Cause Mortality, Myocardial Infarction (MI), or Stroke</title>
          <description>Event Rate of all-cause mortality (ACM), MI, or stroke were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 patient [pt]-year [yr]) = 100*n/(total risk exposure), where n is the number of events.</description>
          <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
          <units>Event rate per 100 patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2507"/>
                <count group_id="O2" value="2515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.44"/>
                    <measurement group_id="O2" value="14.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis 1</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.270</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)</title>
        <description>Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
        <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
        <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Cardio Vascular Death or Re-Hospitalization for Worsening of Heart Failure (RHHF)</title>
          <description>Event rate of cardio vascular (CV) death or re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
          <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
          <units>Event rate per 100 patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2507"/>
                <count group_id="O2" value="2515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.32"/>
                    <measurement group_id="O2" value="23.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Cardio Vascular Death</title>
        <description>Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
        <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
        <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Cardio Vascular Death</title>
          <description>Event rate of cardio vascular death were assessed. CV death included deaths due to spontaneous bleeding, MI, stroke, worsening HF and arrhythmias, death due to CV procedures and sudden death. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
          <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
          <units>Event rate per 100 patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2507"/>
                <count group_id="O2" value="2515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.46"/>
                    <measurement group_id="O2" value="9.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Re-Hospitalization for Worsening of Heart Failure</title>
        <description>Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
        <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
        <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Re-Hospitalization for Worsening of Heart Failure</title>
          <description>Event rate of re-hospitalization for worsening of heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
          <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
          <units>Event rate per 100 patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2507"/>
                <count group_id="O2" value="2515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.24"/>
                    <measurement group_id="O2" value="17.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)</title>
        <description>Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
        <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
        <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Re-Hospitalization for Cardio Vascular Events (RHCV)</title>
          <description>Event rate due to cardio vascular events were assessed. Hospitalization for a CV Event required that participants be hospitalized (in-patient or emergency department) for greater than 24 hours and must have met the following criterion:Discharge summary with primary reason for admission listed as CV in nature (example, bleeding, arrhythmia, ACS, MI) other than HF which was captured in the HF re-hospitalization. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
          <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
          <units>Event rate per 100 patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2507"/>
                <count group_id="O2" value="2515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.30"/>
                    <measurement group_id="O2" value="14.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure</title>
        <description>Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
        <time_frame>Up to Global treatment end date (approximately 54 months)</time_frame>
        <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of All-Cause Mortality (ACM) or Re-Hospitalization for Worsening Heart Failure</title>
          <description>Event rate of all-Cause Mortality (ACM) or re-Hospitalization for worsening heart failure were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
          <population>Intent-to-Treat analysis set included all randomized unique participants who signed a valid informed consent. Participants were analyzed according to the treatment group assigned, irrespective of the actual treatment received.</population>
          <units>Event rate per 100 patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2507"/>
                <count group_id="O2" value="2515"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.84"/>
                    <measurement group_id="O2" value="24.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability</title>
        <description>Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
        <time_frame>Up to 227 Weeks</time_frame>
        <population>Safety Analysis Set included all intent-to-treat participants who received at least one dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Either Fatal Bleeding or Bleeding Into a Critical Space With Potential for Permanent Disability</title>
          <description>Event rate of either fatal bleeding or bleeding into critical space with potential for permanent disability were assessed. Fatal bleeding event was death within 7 days after a bleeding event which required hospitalization or met International Society on Thrombosis and Haemostasis(ISTH) major bleeding definition criteria. Fatal bleeding events included those met criteria in 3 categories: 1: Any ISTH major bleeding event consider primary cause of death by investigator; 2: Any ISTH major bleeding event not considered to be primary cause of death by investigator but resulted in death within 7 days;3: Any bleeding event resulted in hospital stay and death within 7 days. Bleeding into critical space with potential for permanent disability included 7 critical spaces: intracranial, intraspinal, intraocular. Event rate estimated based on time to first occurrence of event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
          <population>Safety Analysis Set included all intent-to-treat participants who received at least one dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure.</population>
          <units>Event rate per 100 patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2499"/>
                <count group_id="O2" value="2509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fatal Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.22"/>
                    <measurement group_id="O2" value="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Critical Space Bleeding with Permanent Disability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32"/>
                    <measurement group_id="O2" value="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis 1 (Fatal Bleeding)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.951</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.41</ci_lower_limit>
            <ci_upper_limit>2.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical Analysis 2 (Bleeding in Critical Space with Potential for Permanent Disability)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.253</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of Bleeding Events That Requiring Hospitalization</title>
        <description>Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
        <time_frame>Up to 227 Weeks</time_frame>
        <population>Safety Analysis Set included all intent-to-treat participants who received at least one dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of Bleeding Events That Requiring Hospitalization</title>
          <description>Event rate of bleeding events and required Hospitalization were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
          <population>Safety Analysis Set included all intent-to-treat participants who received at least one dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure.</population>
          <units>Event rate per 100 patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2499"/>
                <count group_id="O2" value="2509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52"/>
                    <measurement group_id="O2" value="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event</title>
        <description>Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
        <time_frame>Up to 227 Weeks</time_frame>
        <population>Safety Analysis Set included all intent-to-treat participants who received at least one dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Rivaroxaban</title>
            <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
          </group>
        </group_list>
        <measure>
          <title>Event Rate of International Society on Thrombosis and Haemostasis (ISTH) Major Bleeding Event</title>
          <description>Event rate of ISTH major bleeding event were assessed. Event rate estimated based on the time to the first occurrence of the event were reported in the study. Event Rate / (100 pt-yr) = 100*n/(total risk exposure), where n is the number of events.</description>
          <population>Safety Analysis Set included all intent-to-treat participants who received at least one dose of study drug. Here 'N' signifies number of participants who were evaluable for this outcome measure.</population>
          <units>Event rate per 100 patient-year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2499"/>
                <count group_id="O2" value="2509"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04"/>
                    <measurement group_id="O2" value="1.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 54 Months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rivaroxaban</title>
          <description>Participants received 2.5 milligram (mg) tablet of rivaroxaban orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received matching placebo orally twice daily with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="565" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="571" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="479" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="451" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Anaemia Vitamin B12 Deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Aplastic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cardiac Ventricular Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cardiorenal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriovenous Malformation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Buried Penis Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cataract Nuclear</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetic Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Macular Hole</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ophthalmoplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Retinopathy Hypertensive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Subretinal Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Visual Acuity Reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Adhesions</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Abdominal Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Anal Fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Chronic Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Coeliac Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dental Caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diverticulum Intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Duodenal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Erosive Duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastritis Erosive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Sphincter Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hernial Eventration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ileus Paralytic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Incarcerated Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Incarcerated Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Inflammatory Bowel Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Intestinal Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ischaemic Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Large Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Large Intestine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pancreatic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pancreatic Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pancreatitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ulcerative Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Volvulus of Small Bowel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Disuse Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Drug Withdrawal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Heteroplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hyperthermia Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Multiple Organ Dysfunction Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Soft Tissue Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Biliary Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Biliary Dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cardiac Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cholangitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cirrhosis Alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hepatic Function Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hepatic Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hepatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hepatorenal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Liver Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Portal Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Abscess Limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Abscess Soft Tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bronchitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bursitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cellulitis Gangrenous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cholecystitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Chronic Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetic Foot Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetic Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Douglas' Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Enteritis Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Enterobacter Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Escherichia Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Escherichia Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Escherichia Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Escherichia Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Escherichia Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Shigella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Infection Neurological</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Infected Dermal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Infected Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Infective Spondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Intervertebral Discitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lung Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Medical Device Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Myiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pancreas Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Parotid Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pharyngeal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="72" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pneumonia Klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pneumonia Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Post Procedural Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Viral Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bone Fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Burns Third Degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Craniocerebral Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Foreign Body</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gun Shot Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pneumothorax Traumatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Postoperative Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Radiation Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Tibia Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ulna Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Biopsy Pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Biopsy Prostate</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Blood Glucose Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Blood Glucose Fluctuation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Liver Function Test Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Oesophagogastroduodenoscopy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetic Ketosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetic Metabolic Decompensation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Electrolyte Imbalance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Fluid Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic Hyperosmolar Nonketotic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypovolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Insulin-Requiring Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lactic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Metabolic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Type 1 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Type 2 Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gouty Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lumbar Spinal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Osteitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Polymyalgia Rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Spinal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Myeloid Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma of Colon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bladder Cancer Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Brain Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Breast Cancer Stage Ii</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Breast Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bronchial Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cervix Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Chronic Lymphocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Clear Cell Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Colon Cancer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Colon Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Colon Cancer Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Colon Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Colorectal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ear Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Epiglottic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gallbladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastric Cancer Recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hepatic Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hepatic Cancer Stage Iv</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypopharyngeal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Intestinal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lung Carcinoma Cell Type Unspecified Stage Ii</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Malignant Neoplasm of Unknown Primary Site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Metastases to Bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Metastases to Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Metastases to Liver</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Metastases to Lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Metastatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Metastatic Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Monoclonal Gammopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Neoplasm of Orbit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Oesophageal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Plasma Cell Myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Prostate Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Prostate Cancer Stage Iv</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Prostatic Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Rectal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Rectal Cancer Stage Iii</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Rectal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Renal Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Renal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Small Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Small Intestine Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Testis Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Throat Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Tongue Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Tongue Neoplasm Malignant Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amyotrophic Lateral Sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Brain Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Brain Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cervicobrachial Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dizziness Postural</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hemianopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypoglycaemic Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypoxic-Ischaemic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Intercostal Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ischaemic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lumbosacral Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Metabolic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Neuroglycopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Neuropathy Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol Abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Alcohol Withdrawal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Alcoholism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Antisocial Personality Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Anxiety Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Illness Anxiety Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder Due to A General Medical Condition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Self-Injurious Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Chronic Kidney Disease</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetic Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>End Stage Renal Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Iga Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Nephropathy Toxic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Nephrotic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Prerenal Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Renal Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Urethral Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Urinary Tract Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Urinary Tract Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst Torsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bronchitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dyspnoea Paroxysmal Nocturnal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Interstitial Lung Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Lung Infiltration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Necrotising Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pulmonary Mass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Respiratory Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Vocal Cord Thickening</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Dyshidrotic Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypersensitivity Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Necrobiosis Lipoidica Diabeticorum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Rash Generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Rash Macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Toxic Epidermal Necrolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Anal Sphincterotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Bile Duct Stent Removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Breast Tumour Excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cataract Operation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Chemotherapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cyst Removal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Management</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Drug Therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hernia Repair</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Ileostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia Repair</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Insertion of Ambulatory Peritoneal Catheter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Leg Amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Peripheral Artery Bypass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Prosthetic Vessel Implantation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Removal of Ambulatory Peritoneal Catheter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Spinal Fusion Surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Spinal Laminectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Transurethral Prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Aortic Dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Arterial Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Cryoglobulinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Diabetic Vascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Extremity Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Hypovolaemic Shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Peripheral Vascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Phlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Subclavian Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Version 20.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="2507"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="2515"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>SENIOR DIRECTOR, CLINICAL LEADER CV</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <phone>844-434-4210</phone>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

